InVitria Attends 11th Annual World Vaccine Congress
|| Print ||
|Thursday, 07 April 2011 18:15 (UTC + 2)|
The vaccine industry’s move toward cell-based vaccines increases demand for InVitria’s animal-free product line to eliminate contamination risk and improve performance.
One common challenge to cell culture-based viral vaccine production is a heavy reliance on animal components, such as fetal bovine serum (FBS), trypsin, and animal- or human blood-derived albumins. Cells that are used in these cultures have traditionally required media ingredients with animal components to achieve the desired growth and productivity. However, animal-derived ingredients are undesirable because they are intrinsically undefined and often create batch-to-batch variability that leads to unpredictable results. In addition, use of these products has been discouraged by the US Food and Drug Administration (FDA) and other global regulatory bodies due to safety concerns involving the risk of viral and prion (the infectious causative agent associated with Mad Cow Disease) contamination.
InVitria’s product line eliminates these manufacturing challenges by providing direct replacements for animal components. InVitria’s products are animal-free and defined, resulting in a regulatory-friendly cell-based vaccine production system that is safer, more robust, and more consistent than animal-derived alternatives.
“The vaccine industry is rapidly moving towards producing more vaccines in cell culture systems because of the clear advantages provided,” said Shawn Smith, Vice President of Sales & Marketing for InVitria. “A key component to the success of this movement is the ability to produce the vaccines in an animal-free system. InVitria’s products are designed to address this issue by replacing the common bovine and human serum-derived components used today.”